Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Procurement

Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure

Bone Marrow Transplantation volume 47, pages 1403–1408 (2012)Cite this article

Subjects

Abstract

Lenalidomide is associated with suboptimal autologous hematopoietic stem cell (AHSC) mobilization. We hypothesized that growth factor plus preemptive plerixafor is an effective strategy for AHSC mobilization in multiple myeloma (MM) despite prior exposure to lenalidomide. We retrospectively reviewed patient characteristics and mobilization outcomes of 89 consecutive MM patients undergoing first mobilization with filgrastim or pegfilgrastim +/− preemptive plerixafor using a previously validated algorithm based on day 4 peripheral blood CD34+ cell count (PB-CD34+) and mobilization target. Outcomes were analyzed according to the extent of prior exposure to lenalidomide: no prior exposure (group A, n=40), 1– 4 cycles (group B, n=30) and >4 cycles (group C, n=19). Multivariate analysis yielded only age and number of cycles of lenalidomide as negatively associated, and mobilization with pegfilgrastim as positively associated with higher PB-CD34+. Only 45% of patients in group A required plerixafor vs 63% in groups B and 84% in C, P=0.01. A higher proportion of patients in group A (100%) met the mobilization target than in groups B (90%) or C (79%), P=0.008. All patients yielded at least 2 × 106 CD34+/kg. Growth factor mobilization with preemptive plerixafor is an adequate upfront mobilization strategy for MM patients regardless of prior exposure to lenalidomide.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  Google Scholar 

  2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  Google Scholar 

  3. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the group myelome-autogreffe. J Clin Oncol 2005; 23: 9227–9233.

    Article  CAS  Google Scholar 

  4. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29–37.

    Article  CAS  Google Scholar 

  5. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116: 679–686.

    Article  CAS  Google Scholar 

  6. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28: 4621–4629.

    Article  CAS  Google Scholar 

  7. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035–2042.

    Article  CAS  Google Scholar 

  8. Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S . Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008; 22: 1280–1281; author reply 1281–1282.

    Article  CAS  Google Scholar 

  9. Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda VJ, Pirooz N et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008; 22: 1282–1284.

    Article  CAS  Google Scholar 

  10. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 718–723.

    Article  Google Scholar 

  11. Cavallo F, Bringhen S, Milone G, Ben-Yehuda D, Nagler A, Calabrese E et al. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia 2011; 25: 1627–1631.

    Article  CAS  Google Scholar 

  12. Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 2008; 14: 795–798.

    Article  CAS  Google Scholar 

  13. Nazha A, Cook R, Vogl DT, Mangan PA, Gardler M, Hummel K et al. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen. Bone Marrow Transplant 2011; 46: 59–63.

    Article  CAS  Google Scholar 

  14. Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant 2011; 46: 523–528.

    Article  CAS  Google Scholar 

  15. Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman S, Litzow MR et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006; 6: 384–388.

    Article  CAS  Google Scholar 

  16. Schwartzberg LS, Birch R, Hazelton B, Tauer KW, Lee P, Altemose R et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992; 1: 317–327.

    Article  CAS  Google Scholar 

  17. Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, Macpherson J, Winkler K et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011; 17: 729–736.

    Article  CAS  Google Scholar 

  18. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726.

    CAS  Google Scholar 

  19. Malard F, Kroger N, Gabriel IH, Hubel K, Apperley JF, Basak GW et al. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biol Blood Marrow Transplant 2012; 18: 314–317.

    Article  CAS  Google Scholar 

  20. Micallef IN, Ho AD, Klein LM, Marulkar S, Gandhi PJ, McSweeney PA . Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. Bone Marrow Transplant 2010; 46: 350–355.

    Article  Google Scholar 

  21. Sinha S, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK et al. Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies. Leukemia 2012; 26: 1119–1122.

    Article  CAS  Google Scholar 

  22. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK . Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011; 46: 64–69.

    Article  CAS  Google Scholar 

  23. Costa LJ, Hogan KR, Kramer C, Butcher C, Littleton A, Shoptaw KB et al. Comparison between pegfilgrastim and filgrastim-based autologous hematopoietic stem cell mobilization in the setting of patient adapted (‘just in time’) plerixafor: efficacy and cost analysis. Blood 2011; 118 (abstract 1921).

  24. Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant 2011; 46: 523–528.

    Article  CAS  Google Scholar 

  25. Alexander ET, Towery JA, Miller AN, Kramer C, Hogan KR, Squires JE et al. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and day +100 hematopoietic graft function. Transfusion 2011; 51: 1995–2000.

    Article  Google Scholar 

  26. Sinha S, Gastineau D, Micallef I, Hogan W, Ansell S, Buadi F et al. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant 2011; 46: 943–949.

    Article  CAS  Google Scholar 

  27. Abhyankar S, Dejarnette S, Aljitawi O, Ganguly S, Merkel D, McGuirk J . A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant 2012; 47: 483–487.

    Article  CAS  Google Scholar 

  28. Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ et al. Effectiveness and cost analysis of ‘just-in-time’ salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011; 51: 2175–2182.

    Article  Google Scholar 

  29. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.

    Article  CAS  Google Scholar 

  30. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104: 3052–3057.

    Article  CAS  Google Scholar 

  31. Boccadoro M, Palumbo A, Bringhen S, Merletti F, Ciccone G, Richiardi L et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002; 87: 846–850.

    CAS  PubMed  Google Scholar 

  32. Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Haas R . Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736–744.

    Article  CAS  Google Scholar 

  33. Jansen J, Thompson J, Dugan M, Wiemann M, Hanks S, Greenspan A et al. Impaired PBPC collection in patients with myeloma after high-dose melphalan. Cytotherapy 2004; 6: 498–504.

    Article  CAS  Google Scholar 

  34. Davies F, Baz R . Lenalidomide mode of action: linking bench and clinical findings. Blood Rev 2010; 24(Suppl 1): S13–S19.

    Article  Google Scholar 

  35. Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998; 16: 1547–1553.

    Article  CAS  Google Scholar 

  36. Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 2009; 15: 249–256.

    Article  CAS  Google Scholar 

  37. Tricot G, Cottler-Fox MH, Calandra G . Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010; 45: 63–68.

    Article  CAS  Google Scholar 

  38. Micallef I, Sinha S, Gastineau D, Wolf R, Inwards D, Gertz M et al. A cost effective analysis of a risk-adapted algorithm for plerixafor use in autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2011; 17: S159–S160.

    Article  Google Scholar 

  39. Vishnu P, Roy V, Paulsen A, Zubair AC . Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2012; 52: 55–62.

    Article  CAS  Google Scholar 

  40. Anwer F, Green MR, Yeager AM . Effective primary mobilization of autologous peripheral blood stem cells with granulocyte colony-stimulating factor and plerixafor in lenalidomide-treated patients with multiple myeloma. ASH Annu Meet Abstr 2010; 116: 2254.

    Google Scholar 

  41. Schulman KA, Birch R, Zhen B, Pania N, Weaver CH . Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol 1999; 17: 1227.

    Article  CAS  Google Scholar 

  42. Scheid C, Draube A, Reiser M, Schulz A, Chemnitz J, Nelles S et al. Using at least 5 × 10(6)/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation. Bone Marrow Transplant 1999; 23: 1177–1181.

    Article  CAS  Google Scholar 

  43. Lefrere F, Delarue R, Somme D, Levy V, Damaj G, Tu A et al. High-dose CD34+ cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose. Transfusion 2002; 42: 443–450.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, USA

    L J Costa, J Abbas, K R Hogan, C Kramer, K McDonald, C D Butcher, A Littleton, K Shoptaw, Y Kang & R K Stuart

Authors
  1. L J Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Abbas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K R Hogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Kramer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K McDonald
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C D Butcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Littleton
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Shoptaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R K Stuart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L J Costa.

Ethics declarations

Competing interests

LJC received honorarium from Sanofi-Genzyme. The other authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Costa, L., Abbas, J., Hogan, K. et al. Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant 47, 1403–1408 (2012). https://doi.org/10.1038/bmt.2012.60

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.60

Keywords

This article is cited by

Search

Advanced search

Quick links